Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01690507
Other study ID # CN301-XYK-001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received September 19, 2012
Last updated February 23, 2016
Start date November 2012
Est. completion date January 2016

Study information

Verified date February 2016
Source Chinese PLA General Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

Demethylating agent decitabine enhances the immunogenicity of leukemia cells by inducing the expression of cancer testis antigens (CTAs),MHC class I and II molecules,costimulatory molecules and adhesion molecules. The leukemias cells treated by decitabine will become more sensitive to the following adoptive T cell therapy.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date January 2016
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender Both
Age group 55 Years to 75 Years
Eligibility PATIENT Inclusion Criteria:

- Must have a diagnosis of MDS-RAEB or AML based on 2008 World Health Organization (WHO) classification of myeloid malignancies

- Must have life expectancy >= 3 months

- Must have the ability to observe the efficacy and events

- Must have no accompany therapy(including steroid)

- Patient must have ability to understand and willingness to provide written informed consent prior to participation in the study and any related procedures being performed

- Must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 3

- Must have haploidentical donor

DONOR Inclusion Criteria:

- Must have signed the standard informed consent form; if sufficient cryopreserved cells remain from a previous donation, no additional donation or consent is required

- Both men and women and members of all races and ethnic groups are eligible for this trial

PATIENT Exclusion Criteria:

- Must not have an advanced malignant hepatic tumor

- Must not receive any other forms of chemotherapy after cell infusion during the treatment protocol

- Must not be receiving any other investigational agents within 14 days of first dose of study drug

- Must not have uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements

- Must not be pregnant or breastfeeding; pregnant women are excluded from this study because decitabine is a Category D agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with decitabine, breastfeeding should be discontinued if the mother is treated with decitabine; these potential risks may also apply to other agents used in this study

- Must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the study

- Must not have a known or suspected hypersensitivity to decitabine

- Must not be human immunodeficiency virus (HIV)-positive and on combination antiretroviral therapy; these patients are ineligible because of the potential for pharmacokinetic interactions with decitabine; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

DONOR Exclusion Criteria:

- Must not have any underlying conditions which would contra-indicate apheresis

- Must not be pregnant

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Decitabine
20 mg/m²/day for 5 days
Cytarabine

aclacinomycin

Granulocyte colony-stimulating factor

Other:
HLA haploidentical mononuclear cells infusion


Locations

Country Name City State
China Chinese PLA General Hospital Beijing
China Navy General Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Chinese PLA General Hospital Navy General Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary CR rate 3 months Yes
Secondary overall survival 2 years Yes
See also
  Status Clinical Trial Phase
Completed NCT03118466 - Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06313437 - Revumenib in Combination With 7+3 + Midostaurin in AML Phase 1
Withdrawn NCT03444649 - Epacadostat, Idarubicin and Cytarabine (EIC) in AML Phase 1
Withdrawn NCT02905994 - Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Phase 1
Recruiting NCT02261779 - Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Phase 1/Phase 2
Completed NCT00246649 - Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia N/A
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Terminated NCT04079738 - Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib Phase 1/Phase 2
Completed NCT03466320 - DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Phase 1/Phase 2
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Terminated NCT01570465 - Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
Completed NCT04443751 - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 1
Terminated NCT03761069 - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Phase 1
Completed NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia N/A
Completed NCT02575963 - Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients Phase 1/Phase 2
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Completed NCT00780598 - Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Phase 2
Completed NCT00761449 - Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 Phase 2
Completed NCT00542971 - Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Phase 1/Phase 2
Completed NCT00589082 - DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML Phase 3